New drug approved for irritable bowel, chronic constipation

August 30, 2012

(HealthDay)—Linzess (linaclotide) has been approved by the U.S. Food and Drug Administration to treat forms of chronic constipation that don't respond to traditional treatment, and irritable bowel syndrome accompanied by constipation, the agency said Thursday in a news release.

The National Institutes of Health estimates that some 63 million people are affected by chronic constipation, and about 15.3 million have (IBS), the FDA said.

Linzess is taken once daily on an empty stomach, at least 30 minutes before the first meal. The most frequently noted adverse reaction is diarrhea.

The drug's label contains a boxed warning that it shouldn't be taken by people aged 16 or younger, the FDA said.

Linzess is produced by Cambridge, Mass.-based Ironwood Pharmaceuticals.

Explore further: California woman finds ways to control IBS

More information: Medline Plus has more about constipation.


Related Stories

California woman finds ways to control IBS

July 5, 2012
(HealthDay) -- Rachel Byrd doesn't remember a time before she had stomach pain and digestive issues. But her symptoms got so bad in 2009 that she rushed to the hospital, thinking her appendix had burst because the pain was ...

Psychological traumas experienced over lifetime linked to adult irritable bowel syndrome

October 31, 2011
The psychological and emotional traumas experienced over a lifetime -- such as the death of a loved one, divorce, natural disaster, house fire or car accident, physical or mental abuse -- may contribute to adult irritable ...

Researchers identify drugs with fewest side-effects for treating irritable bowel syndrome

March 26, 2012
Cedars-Sinai researchers have determined that two prevalent drug therapies – rifaximin and lubiprostone – offer some of the best options for treating irritable bowel syndrome, a widespread disorder that affects ...

Marqibo approved for ph- acute lymphoblastic leukemia

August 10, 2012
(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with Philadelphia chromosome negative acute lymphoblastic leukemia (ALL).

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.